Prognostic and predictive molecular biomarkers in breast cancer

The Austrian Breast & Colorectal Cancer Study Group (ABCSG) is very successful in standardizing and continuously improving treatment of breast- and colorectal cancer in Austria. Sophisticated and courageous clinical trials, the reliance of more than 20.000 participants and maximum efforts of the 100 ABCSG centers made this possible. This story of success meanwhile positioned the ABCSG within Europe’s top-elite academic trials study groups.
In order to improve treatment of women with breast cancer, we study the clinical relevance of prognostic and predictive biomarkers in breast cancer patients enrolled into ABCSG trials.